Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer
Lorenzo Belluomini1, Alice Avancini1,2, Marco Sposito1
1Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Introduction:
The advent of antibody-drug conjugates (ADCs) represents a renewed strategy in the era of precision oncology. Several epithelial tumors harbor overexpression of the trophoblast cell-surface antigen 2 (TROP-2), which represents a predictor of poor prognosis and a promising target for anticancer therapy.
Areas Covered:
In this review, we aim to collect the available preclinical and clinical data regarding anti-TROP-2 ADCs in lung cancer obtained through extensive literature research and screening of the available abstract/posters presented at recent meetings.
Expert Opinion:
Anti-TROP-2 ADCs represent an innovative upcoming weapon against both non-small cell lung cancer and small cell lung cancer subtypes, pending the results of several ongoing trials. The proper combination and placement of this agent throughout the lung cancer treatment pathway, the identification of potentially predictive biomarkers of benefit, as well as the optimal management and impact of peculiar toxicity (i.e. interstitial lung disease) are the next questions to be answered.
Insights
Antibody-drug conjugates targeting TROP-2 show promise for lung cancer treatment. Further research is needed to optimize their use and manage potential toxicities like interstitial lung disease.
Area of Science:
- Oncology
- Pharmacology
Background:
- Trophoblast cell-surface antigen 2 (TROP-2) is overexpressed in several epithelial tumors, including lung cancer, and is associated with poor prognosis.
- TROP-2 represents a promising therapeutic target for developing novel anticancer agents.
Approach:
- This review systematically collected and analyzed preclinical and clinical data on anti-TROP-2 antibody-drug conjugates (ADCs).
- Literature research and screening of recent scientific meeting abstracts/posters were conducted to gather relevant information.
Key Points:
- Anti-TROP-2 ADCs are emerging as a significant therapeutic strategy for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
- Ongoing clinical trials are evaluating the efficacy and safety of these novel agents.
Conclusions:
- Further investigation is required to determine the optimal integration of anti-TROP-2 ADCs into lung cancer treatment paradigms.
- Identifying predictive biomarkers and understanding the management of specific toxicities, such as interstitial lung disease, are crucial next steps.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy